Rescheduled - Dr. Jason Sicklick of Moores Cancer Center at UCSD will present a webcast detailing the Phase II study of Temozolomide in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.
During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.
This discussion will review Cancer-related cognitive impairment (CRCI) in general, and how a person who is being treated for GIST could be affected. We will also talk about strategies that can help ameliorate CRCI and discuss our new research on CRCI and GIST.
In this webinar, we will be discussing how to interpret your pathology report. We will cover interpretation of all parts of a pathology report, beginning with understanding the final diagnosis and diagnostic comment.
The September webcast will feature an interactive panel of women sarcoma experts sharing their expertise as powerful advocates working on behalf of those living with sarcoma.
With the alphabet soup of terms and genes that cancer patients tend to hear during diagnosis, it takes some time to really understand what these terms mean. In her Genetics 101 webcast, Dr. Raygada [...]
Case Presentations October 26, 12PM ET Please join us for the second webcast of our Women in Sarcoma series. The Life Raft Group has developed the Women in Sarcoma program in recognition of the [...]
At this Virtual Awards Gala, as we aim to highlight women in sarcoma (both medical professionals and patients) who make a difference in patients’ lives, and to inspire the community with their stories and perspectives of women’s role in oncology as well as their personal experiences.
Please be aware of the time difference: This webinar takes place on Feb 4th at 7pm ET for the US and Feb 5th at 11 am Melbourne time.) Please join us for a Virtual [...]
Dr. Justin Annes will review the hPPGL Syndrome with particular focus on the underlying genetics basis and related tumor risks and the benefits/limitations of genetic testing and pre-symptomatic screening.
Every GIST patient is unique based on their biology and what treatment to which they will potentially respond. Dr. Lori Rink, Fox Chase Cancer Center, and Dr. Inga-Marie Schaefer, Brigham & Women’s Hospital, are two researchers who are making discoveries in their respective laboratories to uncover the unique biomarkers in GIST that will be future drug targets.
Risks, Management, and What to Know for You and Your Family In this webinar, we will review what is known about the hereditary causes behind GISTs, current genetic testing options and results, how this [...]
